Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Circulation: Heart Failure

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCHEARTFAILURE.107.748343PMID 19808314PMCID PMC2764958
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathophysiology of chronic heart failure.

  2009cited by this paper
• Sex-based differences in myocardial contractile reserve.

  2007cited by this paper
• Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overload.

  2007cited by this paper
• The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

  2006cited by this paper
• Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

  2006cited by this paper
• Effect of endothelins on the cardiovascular system

  2006cited by this paper
• Activation of calcineurin in human failing heart ventricle by endothelin‐1, angiotensin II and urotensin II

  2005cited by this paper
• Neurohormonal activation in congestive heart failure and the role of vasopressin.

  2005cited by this paper
• Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications.

  2005cited by this paper
• Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.

  2004cited by this paper
• Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators

  2004cited by this paper
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cited by this paper
• Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.

  2004cited by this paper
• Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardium.

  2004cited by this paper
• [Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion].

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Plasma Urotensin in Human Systolic Heart Failure

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart Disease

  2002cited by this paper
• Cardiostimulant effects of urotensin‐II in human heart in vitro

  2001cited by this paper
• Pathophysiology of chronic heart failure.

  2001cited by this paper
• Patients With End-Stage Congestive Heart Failure Treated With &bgr;-Adrenergic Receptor Antagonists Have Improved Ventricular Myocyte Calcium Regulatory Protein Abundance

  2001cited by this paper
• Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

  2000cited by this paper
• Hormones and hemodynamics in heart failure.

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Contribution of reverse-mode sodium-calcium exchange to contractions in failing human left ventricular myocytes.

  1998cited by this paper
• Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure.

  1998cited by this paper
• The trabecula culture system: a novel technique to study contractile parameters over a multiday time period.

  1998cited by this paper
• The trabecula culture system: a novel technique to study contractile parameters over a multiday time period.

  1998cited by this paper
• Pathophysiology of chronic heart failure.

  1992cited by this paper

• Enhanced negative modulation of urotensin II on cardiac function and [Ca2+]i regulation in a diabetic rat model: Insights into molecular and cellular mechanisms.

  2025cites this paper
• Urotensin II Receptor Modulation with 1,3,4-Benzotriazepin-2-one Tetrapeptide Mimics.

  2023cites this paper
• Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists.

  2019cites this paper
• Novel insights into the role of urotensin II in cardiovascular disease.

  2019cites this paper
• Urantide Improves Cardiac Function, Modulates Systemic Cytokine Response and Increases Survival in a Murine Model of Endotoxic Shock.

  2019cites this paper
• Effects of Urotensin II on Excitation-Contraction Coupling in Hypertrophic Heart Failure

  2018influential citation
• Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics.

  2017cites this paper
• Engineering Cardiac Muscle Tissue: A Maturating Field of Research.

  2017cites this paper
• A novel urotensin II receptor antagonist, KR‐36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure

  2017cites this paper
• Synthèse en phase solide de pyrrolo[3,2-e][1,4]diazépin-2-ones modulateurs du système urotensinergétique

  2017cites this paper
• Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists.

  2016cites this paper
• The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

  2016cites this paper
• A Myocardial Slice Culture Model Reveals Alpha-1A-Adrenergic Receptor Signaling in the Human Heart

  2016cites this paper
• De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one γ-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo.

  2015cites this paper
• 1,3,4‐Thiadiazol‐2‐amine Derivatives as Urotensin‐II Receptor (UT) Antagonists

  2015cites this paper
• The Importence of Urotensin and Urotensin Receptors in Cardiovascular System

  2014cites this paper
• Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease.

  2014cites this paper
• Molecular evolution of GPCRs: Somatostatin/urotensin II receptors.

  2014cites this paper
• Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.

  2014cites this paper
• Analysis of genetic variation within urotensin-II system in regulation of blood pressure and renal function

  2013cites this paper
• Contractile responses to rat urotensin II in resting and depolarized basilar arteries

  2013cites this paper
• Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium

  2012cites this paper
• GSK1562590, a slowly dissociating urotensin‐II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

  2010cites this paper